Skip to content

Inspection Record

Sanrace Biotechnology Co., Ltd. — FDA Warning Letter Findings

US FDAPublished 2026-10-27 3 findingsProcess validationQuality unit oversightMaterial and supplier control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Process validation

Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)). Based on the records and information you provided, you did not demonstrate that your manufacturing processes are reproducible and controlled to yield a product of uniform character and quality. Specifically, your response states that your firm does not have process validation procedures or process validation studies. Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing of throughout each significant process stage to characterize intra-batch variation and evaluates batches to determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https://www.fda.gov/media/71021/download.

2Quality unit oversight

Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)). Based on the records and information you provided, your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure: Adequate laboratory control procedures to ensure drug products conform to appropriate standards of identity, strength, quality and purity (21 CFR 211.160(b). Specifically, the records you provided demonstrate that you lack an adequate (b)(4) system monitoring program. The procedures you provided and (b)(4) test results lacked adequate testing for attributes such as (b)(4) . The establishment of an adequate ongoing stability program (21 CFR 211.166(a)). For example, the records and information you provided lacked complete stability data and complete stability testing. Specifically, your records did not document viscosity, pH, assay, and microbiological testing to ensure that your drug products meet all quality attributes throughout their shelf-life. Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents Quality Systems Approach to Pharmaceutical CGMP Regulations at https://www.fda.gov/media/71023/download. CGMP Consultant Recommended Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.

3Material and supplier control

Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)). Your firm manufactures OTC drug products including (b)(4) . Based on the records and information you provided, you did not demonstrate that you adequately tested the identity of incoming components (e.g., (b)(4) ) used in the manufacture of your drug products. (b)(4) You failed to adequately test your incoming (b)(4) , used as an active ingredient in your drug products, for (b)(4) . The use of (b)(4) contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4) . (b)(4) Identity testing for (b)(4) and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure that the components meet the relevant safety limits for levels of (b)(4) . Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products. The use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4) . Without adequate testing, you do not have scientific evidence that your components conform to appropriate specifications prior to use in the manufacture of your drug products.

Sections cited in this document

A record as of the US FDA document published on 2026-10-27. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Sanrace Biotechnology Co., Ltd. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.